Several studies have been reported in modulating oxysterol metabolic enzymes (i.e., Cyp7b1 and Sult2b1) with the purpose of improving NASH-related hepatic conditions. The gene discussed is CYP7B1; the disease is metabolic dysfunction-associated steatohepatitis.